Last updated: February 19, 2026
This analysis examines Australian patent AU2006322076, detailing its claims, scope, and the surrounding patent landscape. The patent, titled "Pharmaceutical Composition and Method of Treatment," was filed on December 11, 2006, and granted to Pfizer Inc. on January 30, 2014. It claims a specific pharmaceutical composition containing 2-(4-{[3-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]methoxy}phenyl)acetic acid (also known as Palovarotene) and a pharmaceutically acceptable carrier, for use in treating fibrodysplasia ossificans progressiva (FOP).
What are the core claims of AU2006322076?
The patent's claims define the intellectual property protection granted. They specify the protected subject matter, including the compound, its formulations, and its therapeutic applications.
Independent Claims
- Claim 1: This claim defines the primary invention: a pharmaceutical composition comprising 2-(4-{[3-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]methoxy}phenyl)acetic acid and a pharmaceutically acceptable carrier. This is the central inventive entity of the patent.
- Claim 6: This claim extends protection to the method of treating fibrodysplasia ossificans progressiva (FOP) by administering a therapeutically effective amount of the pharmaceutical composition defined in Claim 1. This claim covers the therapeutic use of the patented compound.
Dependent Claims
The patent includes numerous dependent claims that further narrow and elaborate on the independent claims, providing layered protection. These claims specify various aspects of the composition and its use.
- Claims 2-5: These claims define specific formulations of the composition. For example, Claim 2 specifies a solid oral dosage form. Claim 3 mentions a tablet. Claim 4 details the amount of the active ingredient, specifying it as 1 mg to 500 mg of 2-(4-{[3-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]methoxy}phenyl)acetic acid. Claim 5 refers to a specific salt form, namely Palovarotene hydrochloride.
- Claims 7-10: These claims further define the method of treatment. Claim 7 specifies that the FOP is characterized by heterotopic ossification. Claim 8 defines the dosage, stating administration is in an amount effective to inhibit, reduce, or prevent heterotopic ossification. Claim 9 specifies a dosage range, such as 1 mg to 500 mg of the active ingredient. Claim 10 refers to a specific administration frequency, such as once a day.
What is the scope of protection afforded by AU2006322076?
The scope of protection is determined by the breadth of the claims, particularly the independent claims, and how they are interpreted within the framework of Australian patent law.
The patent protects Palovarotene and its specific formulation for the treatment of FOP. The scope is focused on the compound itself and its use in a particular disease. The claims are structured to cover both the product (the composition) and the method of using it for a defined medical condition. The inclusion of specific dosage ranges and salt forms within the dependent claims strengthens the protection by covering variations of the core invention.
The protection extends to any pharmaceutical composition containing Palovarotene and a pharmaceutically acceptable carrier that is intended for treating FOP. This includes different dosage forms and strengths, as long as they fall within the scope defined by the claims and their interpretation. The method of treatment claims protect the act of administering Palovarotene to a patient diagnosed with FOP, aiming to inhibit or reduce heterotopic ossification.
What is the key compound and its therapeutic indication?
The central chemical entity is 2-(4-{[3-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]methoxy}phenyl)acetic acid, identified as Palovarotene. The sole therapeutic indication claimed is the treatment of fibrodysplasia ossificans progressiva (FOP).
- Compound Name: 2-(4-{[3-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]methoxy}phenyl)acetic acid
- Common Name/Development Code: Palovarotene
- Therapeutic Indication: Fibrodysplasia Ossificans Progressiva (FOP)
- Mechanism of Action (Implied): The patent does not explicitly detail the mechanism of action but implies its role in inhibiting, reducing, or preventing heterotopic ossification, a hallmark of FOP. Palovarotene is a retinoid receptor gamma (RARγ) agonist. Retinoids are known to regulate gene expression involved in bone development and ossification.
Who is the patent holder and what is its significance?
Pfizer Inc. is the assignee of AU2006322076. Pfizer is a major global pharmaceutical company with a substantial portfolio of patented drugs and a significant presence in research and development. The assignment to Pfizer indicates a commercial interest in developing and marketing Palovarotene.
The significance of Pfizer holding this patent lies in their capacity to commercialize the drug. This includes conducting further clinical trials, obtaining regulatory approvals (e.g., from the Therapeutic Goods Administration in Australia), and manufacturing and distributing Palovarotene. As the patent holder, Pfizer has exclusive rights to exploit the invention in Australia for the patent's term, preventing competitors from making, using, or selling the patented composition or method of treatment without a license.
What is the patent prosecution history and status?
Understanding the prosecution history and current status of the patent provides insight into its validity and remaining term.
- Filing Date: December 11, 2006
- Publication Date: June 12, 2008 (as WO2006/125350A1 via PCT application) [1]
- National Phase Entry in Australia: December 11, 2006 (aligns with international filing date for PCT)
- Grant Date: January 30, 2014
- Patent Term: Patents in Australia are generally granted for a term of 20 years from the filing date. For AU2006322076, the filing date is December 11, 2006. Therefore, the patent is expected to expire on December 11, 2026, unless extended.
- Current Status: Active and granted.
The prosecution history, if accessed through the Australian Patent Office database, would reveal communications between the patent applicant (Pfizer) and the patent examiner. This would include any objections raised, amendments made to the claims, and arguments presented to overcome rejections. Such details can inform an understanding of claim interpretation and potential vulnerabilities.
What is the competitive patent landscape for Palovarotene and FOP treatments?
The competitive landscape involves other entities that may hold patents related to Palovarotene, FOP, or similar therapeutic approaches. Analyzing this landscape is crucial for assessing market entry and potential patent infringement risks.
While AU2006322076 specifically protects Pfizer's Palovarotene composition and method for FOP, other entities may hold patents covering:
- Alternative compounds for FOP treatment: Different chemical entities or classes of drugs that target FOP mechanisms.
- Different therapeutic uses of Palovarotene: If Palovarotene has been investigated for other conditions, related patents might exist.
- Manufacturing processes for Palovarotene: Novel or improved methods of synthesizing the compound.
- Formulations not covered by AU2006322076: Variations in drug delivery systems or excipients that could fall outside the scope of the current patent.
- Broader retinoid-related patents: Patents covering retinoid pathways or other RAR agonists could have indirect relevance.
Key players and potential competitors in the FOP treatment space include:
- Ipsen Biopharmaceuticals: Known to be developing palovarotene (under the name "Sohonos"). Ipsen acquired Clementia Pharmaceuticals in 2019, which had developed palovarotene. Ipsen has pursued regulatory approvals for palovarotene in various jurisdictions.
- Other research institutions and smaller biotech companies: These may be involved in early-stage research for novel FOP therapies.
Analysis of Patent Filings:
A comprehensive search of patent databases (e.g., WIPO's PATENTSCOPE, Espacenet, USPTO, IP Australia) using keywords such as "Palovarotene," "fibrodysplasia ossificans progressiva," "RAR gamma agonist," and relevant chemical structures, would reveal the extent of patenting activity.
- AU2018273331 A1 (Ipsen Biopharmaceuticals): This application, related to pharmaceutical formulations of palovarotene, demonstrates competitive activity. Filed on October 11, 2018, it indicates ongoing innovation and patenting efforts by a direct competitor regarding palovarotene.
- AU2015222272 A1 (Clementia Pharmaceuticals Inc.): Filed on March 11, 2015, this application pertains to methods for treating FOP with palovarotene. Clementia Pharmaceuticals was the original developer of palovarotene before its acquisition by Ipsen. This shows earlier patenting efforts by the company that pioneered palovarotene development.
The existence of these competitor applications suggests an active and evolving patent landscape around palovarotene and FOP treatments. Companies seeking to enter this market must carefully navigate these existing and pending patents to avoid infringement.
What are the potential infringement risks for third parties?
Third parties looking to develop or market drugs for FOP in Australia face potential infringement risks related to AU2006322076.
- Direct Infringement: Any entity that manufactures, uses, sells, or imports a pharmaceutical composition containing Palovarotene and a pharmaceutically acceptable carrier for the treatment of FOP in Australia would directly infringe Claim 1 and potentially dependent claims.
- Method of Treatment Infringement: Administering Palovarotene to treat FOP in Australia would infringe Claim 6 and dependent method claims. This could apply to healthcare providers or entities marketing such treatments.
- Indirect Infringement: Supplying Palovarotene or a composition thereof to another party, knowing that it is to be used for treating FOP in a way that infringes the patent, could also constitute indirect infringement, depending on Australian patent law provisions regarding induced infringement.
Given that the patent is held by Pfizer and that Ipsen has been actively developing palovarotene, any new entrant or existing competitor must conduct thorough freedom-to-operate (FTO) analyses. This involves mapping their proposed product and activities against the scope of AU2006322076 and other relevant patents in the Australian jurisdiction. The expiry date of December 11, 2026, provides a timeframe for when generic competition might be possible, assuming no patent extensions are granted.
Key Takeaways
- Australian patent AU2006322076, granted to Pfizer Inc., protects Palovarotene (2-(4-{[3-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]methoxy}phenyl)acetic acid) and its pharmaceutical composition for treating fibrodysplasia ossificans progressiva (FOP).
- The patent's independent claims cover the composition containing Palovarotene and a pharmaceutically acceptable carrier, and the method of treating FOP with this composition. Dependent claims specify dosage forms, strengths, and administration parameters.
- The patent is active and is set to expire on December 11, 2026.
- The competitive landscape includes other patent applications and development activities by companies like Ipsen Biopharmaceuticals (which acquired the developers of palovarotene) focusing on palovarotene and FOP treatments.
- Third parties seeking to enter the FOP treatment market in Australia must perform rigorous freedom-to-operate analyses to mitigate risks of patent infringement, particularly concerning Palovarotene itself.
FAQs
-
When does Australian patent AU2006322076 expire?
The patent is expected to expire on December 11, 2026, based on its filing date of December 11, 2006.
-
What specific compound does AU2006322076 protect?
The patent protects 2-(4-{[3-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl]methoxy}phenyl)acetic acid, commonly known as Palovarotene.
-
What is the primary therapeutic use claimed for Palovarotene in this patent?
The patent claims the use of Palovarotene for treating fibrodysplasia ossificans progressiva (FOP).
-
Who holds the rights to Australian patent AU2006322076?
The patent holder is Pfizer Inc.
-
Are there other companies actively patenting treatments for FOP that might compete with AU2006322076?
Yes, companies such as Ipsen Biopharmaceuticals have filed patent applications related to palovarotene and FOP treatments, indicating a competitive landscape.
Citations
[1] World Intellectual Property Organization. (2008). PCT International Publication Number WO2006/125350A1. Patent application. Retrieved from [Searchable patent databases like WIPO PATENTSCOPE, Espacenet, or national patent office websites for specific document access].
